Glycopyrrolate/Formoterol Fumarate MDI Compared With Spiriva® as An Active Control in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
Public ClinicalTrials.gov record NCT01587079. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Randomized, Double Blind, (Test Products), Chronic Dosing (7 Days), Four Period, Eight Treatment , Incomplete Block, Cross Over, Multi Center Study to Assess Efficacy and Safety of Five Doses of PT003, One Dose of PT001 and One Dose of PT005 in Patients With Moderate to Severe COPD, Compared With Spiriva® Handihaler® (Tiotropium Bromide 18 µg, Open Label) as Active Control
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The primary objective of this study is to assess the efficacy of Glycopyrrolate/Formoterol Fumarate MDI relative to individual components (GP MDI and FF MDI) in subjects with moderate to severe COPD
Study identification
- NCT ID
- NCT01587079
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 159 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 40 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 31, 2012
- Primary completion
- Aug 31, 2012
- Completion
- Sep 30, 2012
- Last update posted
- Jun 29, 2016
2012
United States locations
- U.S. sites
- 19
- U.S. states
- 14
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Pearl Investigative Site | Glendale | Arizona | — | — |
| Pearl Investigative Site | Rancho Mirage | California | — | — |
| Pearl Investigative Site | Waterbury | Connecticut | — | — |
| Pearl Investigative Site | Clearwater | Florida | 33765 | — |
| Pearl Investigative Site | Clearwater | Florida | — | — |
| Pearl Investigative Site | Pensacola | Florida | — | — |
| Pearl Investigative Site | Winter Park | Florida | 32789 | — |
| Pearl Investigative Site | Lafayette | Louisiana | — | — |
| Pearl Investigative Site | North Dartmouth | Massachusetts | — | — |
| Pearl Investigative Site | Fridley | Minnesota | — | — |
| Pearl Investigative Site | St Louis | Missouri | — | — |
| Pearl Investigative Site | Summit | New Jersey | — | — |
| Pearl Investigative Site | Cincinnati | Ohio | — | — |
| Pearl Investigative Site | Medford | Oregon | 97504 | — |
| Pearl Investigative Site | Medford | Oregon | — | — |
| Pearl Investigative Site | Rock Hill | South Carolina | — | — |
| Pearl Investigative Site | Spartanburg | South Carolina | 29303 | — |
| Pearl Investigative Site | San Antonio | Texas | — | — |
| Pearl Investigative Site | Morgantown | West Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01587079, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 29, 2016 · Synced Sep 3, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01587079 live on ClinicalTrials.gov.